LEADER 03913nam  2200733Ia 450 
001 9910957468703321
005 20251116230952.0
010   $a9786610844333
010   $a9780309133999
010   $a0309133998
010   $a9781280844331
010   $a1280844337
010   $a9780309667111
010   $a0309667119
035   $a(CKB)1000000000522507
035   $a(EBL)3378200
035   $a(SSID)ssj0000277648
035   $a(PQKBManifestationID)11213015
035   $a(PQKBTitleCode)TC0000277648
035   $a(PQKBWorkID)10234779
035   $a(PQKB)10631704
035   $a(MiAaPQ)EBC3378200
035   $a(Au-PeEL)EBL3378200
035   $a(CaPaEBR)ebr10170927
035   $a(CaONFJC)MIL84433
035   $a(OCoLC)923276655
035   $a(Perlego)4735347
035   $a(BIP)14085711
035   $a(EXLCZ)991000000000522507
100   $a20070123d2007      uy         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aCancer biomarkers $ethe promises and challenges of improving detection and treatment  /$fCommittee on Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment, Institute of Medicine of the National Academies ; Sharyl J. Nass and Harold L. Moses, editors
205   $a1st ed.
210   $aWashington, D.C. $cNational Academies Press$dc2007
215   $a1 online resource (252 p.)
300   $aDescription based upon print version of record.
311 08$a9780309103862 
311 08$a030910386X 
320   $aIncludes bibliographical references.
327   $a""Front Matter""; ""Reviewers""; ""Acknowledgments""; ""Contents""; ""Boxes, Figure, and Tables""; ""Summary""; ""1 Introduction""; ""2 Methods, Tools, and Resources Needed to Discover and Develop Biomarkers""; ""3 Guidelines, Standards, Oversight, and Incentives Needed for Biomarker Development""; ""4 Methods and Process Needed for Clinical Adoption and Evaluation of Biomarker-Based Diagnostics""; ""Acronyms and Glossary""
327   $a""Appendix: Developing Biomarker-Based Tools for Cancer Screening, Diagnosis,and Treatment: The State of the Science, Evaluation, Implementation, and Economics, Workshop Summary--Margie Patlak and Sharyl Nass, Rapporteurs""
330   $aMany cancer patients are diagnosed at a stage in which the cancer is too far advanced to be cured, and most cancer treatments are effective in only a minority of patients undergoing therapy. Thus, there is tremendous opportunity to improve the outcome for people with cancer by enhancing detection and treatment approaches. Biomarkers will be instrumental in making that transition. Advances in biotechnology and genomics have given scientists new hope that biomarkers can be used to improve cancer screening and detection, to improve the drug development process, and to enhance the effectiveness and safety of cancer care by allowing physicians to tailor treatment for individual patients-an approach known as personalized medicine. However, progress overall has been slow, despite considerable effort and investment, and there are still many challenges and obstacles to overcome before this paradigm shift in oncology can become a reality.
606   $aTumor markers
606   $aCancer$xDiagnosis
606   $aCancer$xTreatment
615  0$aTumor markers.
615  0$aCancer$xDiagnosis.
615  0$aCancer$xTreatment.
676   $a616.99/4075
701   $aNass$b Sharyl J$0857626
701   $aMoses$b Harold L$01809537
712 02$aNational Academies Press (U.S.)
712 02$aInstitute of Medicine (U.S.).$bCommittee on Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910957468703321
996   $aCancer biomarkers$94364048
997   $aUNINA